lynparza
astrazeneca ab - olaparib - kiaušidžių navikai - antinavikiniai vaistai - kiaušidžių cancerlynparza yra nurodyta kaip monotherapy už:palaikomasis gydymas suaugusiems pacientams, sergantiems išplėstinė (figo etapai iii ir iv) brca1/2-mutavo (germline ir/ar somatinių) aukštos kokybės epitelinis kiaušidžių, kiaušintakių arba pirminės pilvaplėvės vėžys, kuris yra atsakas (visiškas arba dalinis) užbaigus pirmąjį-line platinos pagrindu chemoterapija. maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy. lynparza in combination with bevacizumab is indicated for the:maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (hrd) positive status defined by either a brca1/2 mutation and/or genomic instability (see section 5. breast cancerlynparza is indicated as:monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline brca1/2-mutations who have her2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4. 2 ir 5. monotherapy for the treatment of adult patients with germline brca1/2-mutations, who have her2 negative locally advanced or metastatic breast cancer. pacientams turėtų būti anksčiau buvo elgiamasi su pasirinkusios gydymą antraciklinų ir taxane į (neo)palaikomosios arba metastazavusio nustatymas, išskyrus atvejus, kai pacientams buvo netinkami šių būdų (žr. skyrių 5. pacientams su hormonų receptorių (hr)-teigiamas krūties vėžys taip pat turėtų turėti progresavo d. arba vėliau, prieš endokrininės terapija, arba, laikoma netinkama endokrininę sistemą terapija. adenocarcinoma of the pancreaslynparza is indicated as:monotherapy for the maintenance treatment of adult patients with germline brca1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen. prostate cancerlynparza is indicated as:monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mcrpc) and brca1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent. in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mcrpc in whom chemotherapy is not clinically indicated (see section 5.
lorinden a
bausch health ireland limited - flumetazonas/salicilo rūgštis - tepalas - 0,2 mg/30 mg/g - flumetasone
lorinden c
pharmaswiss Česká republika s.r.o. - flumetazono pivalatas/kliokvinolis - tepalas - 0,2 mg/30 mg/g - flumetasone and antiseptics
advantan milk
leo pharma a/s - metilprednizolono aceponatas - odos emulsija - 1 mg/g - methylprednisolone aceponate
jakavi
novartis europharm limited - ruksolitinibas (fosfatas) - myeloproliferative disorders; polycythemia vera; graft vs host disease - antinavikiniai vaistai - myelofibrosis (mf)jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. polycythaemia vera (pv)jakavi fluorouracilu ir folino suaugusių pacientų su polycythaemia vera, kurie yra atsparūs arba netoleruoja hydroxyurea. graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.
ledaga
helsinn birex pharmaceuticals ltd. - chlormetinas - mikulas fungoides - antinavikiniai vaistai - ledaga skiriama vietiniam mikozės fungoidų tipo odos t ląstelių limfomos (mf tipo ctcl) gydymui suaugusiems pacientams.
diclofenac siromed [diclofenac sopharma]
sopharma ad - diklofenako natrio druska - gelis - 10 mg/g - diclofenac
lamisil dermgel
glaxosmithkline dungarvan limited - terbinafinas - gelis - 10 mg/g - terbinafine
fucicort
leo pharma a/s - fuzido rūgštis/betametazonas - kremas - 20 mg/1 mg/g - betamethasone and antibiotics
baqsimi
eli lilly nederland b.v. - gliukagono - cukrinis diabetas - kasos hormonai, hormonų glycogenolytic - baqsimi fluorouracilu ir folino sunkių blogiau suvokia hipoglikemijos keliamus pavojus suaugusiems, paaugliams ir vaikams nuo 4 metų ir vyresni, su cukriniu diabetu.